A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
12/2002
12/08/2002	CA2386262A1 Method for nasal application of a medicinal substance
12/08/2002	CA2385745A1 Methods of administering anti-tnf.alpha. antibodies
12/05/2002	WO2002097120A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
12/05/2002	WO2002097094A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis
12/05/2002	WO2002097081A2 Method to generate non virulent microorganisms from pathogenic ones trough permanent genetic modification of their biological membrane for vaccine production
12/05/2002	WO2002097075A2 Capping enzyme of flavivirus and utilization of this protein in a process to test drugs with antiviral properties
12/05/2002	WO2002097072A2 Influenza vaccine composition
12/05/2002	WO2002097060A2 Carbohydrate-associated proteins
12/05/2002	WO2002097053A2 Small molecule antagonists of bcl2 family proteins
12/05/2002	WO2002097051A2 Protein arrays and methods and systems for producing the same
12/05/2002	WO2002097046A2 B7 related protein-2 molecules and uses thereof
12/05/2002	WO2002097043A2 Wnv core protein/capsid interacting protein and uses of the same
12/05/2002	WO2002097033A2 Antibodies that immunospecifically bind to trail receptors
12/05/2002	WO2002097030A2 Peptides derived from neural thread proteins and their medical use
12/05/2002	WO2002096952A2 Conjugate of a transport protein and a protein for modulation of notch signalling
12/05/2002	WO2002096943A1 Stat6-activating genes
12/05/2002	WO2002096941A2 Polypeptide which reacts with the antibodies of patients infected by hcv and uses thereof
12/05/2002	WO2002096936A2 Daptomycin and related analogs in crystalline form, their preparation and use
12/05/2002	WO2002096935A2 Long lasting fusion peptide inhibitors for hiv infection
12/05/2002	WO2002096932A1 Transporters and ion channels
12/05/2002	WO2002096929A2 Polypeptides reacting with hcv-infected patients' antibodies and uses
12/05/2002	WO2002096922A1 An arylation method for the functionalization of o-allyl erythromycin derivatives
12/05/2002	WO2002096921A1 Novel glucose derivative inducing apoptosis, process for producing the same, and use thereof as medicine
12/05/2002	WO2002096908A1 Antibacterial agents
12/05/2002	WO2002096907A1 Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials
12/05/2002	WO2002096896A1 Biologically active methylene blue derivatives
12/05/2002	WO2002096892A1 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
12/05/2002	WO2002096888A1 Cdk inhibiting pyrimidines, production thereof and their use as medicaments
12/05/2002	WO2002096883A1 Tricyclic compounds useful as angiotensin ii agonists
12/05/2002	WO2002096876A1 Carbamate and oxamide compounds as inhibitors of cytokine production
12/05/2002	WO2002096867A2 Inhibitors of protein kinase for the treatment of disease
12/05/2002	WO2002096866A2 Thiolalkyl benzoic acid derivatives
12/05/2002	WO2002096864A1 Carboxamide-substituted phenylurea derivatives and method for production thereof as medicaments
12/05/2002	WO2002096467A2 Pharmaceutical use for secreted bacterial effector proteins
12/05/2002	WO2002096457A2 Stable liquid formulations of antibodies
12/05/2002	WO2002096455A2 Use of polyclonal immunoglobulins
12/05/2002	WO2002096453A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin
12/05/2002	WO2002096438A1 Synergistic antibiotic compositions
12/05/2002	WO2002096427A1 Pyrimidine derivatives as selective inhibitors of cox-2
12/05/2002	WO2002096426A1 Hydantion derivatives as inhibitors of matrix metalloproteinases
12/05/2002	WO2002096421A1 5-substituted-2-arylpyridines as crf1 modulators
12/05/2002	WO2002096419A1 Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
12/05/2002	WO2002096396A1 Fine inorganic particles having drug included therein, method for preparation thereof and pharmaceutical preparation comprising fine inorganic particles having drug included therein
12/05/2002	WO2002096395A1 Soft elastic capsules comprising ritonavir and/or lopinavir
12/05/2002	WO2002096367A2 Targeted multivalent macromolecules
12/05/2002	WO2002096366A2 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
12/05/2002	WO2002096360A2 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
12/05/2002	WO2002096354A2 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
12/05/2002	WO2002096349A2 Vaccination against the feline immunodeficiency virus
12/05/2002	WO2002096224A1 Oral composition comprising an extract from the bark of albizzia myriophylla
12/05/2002	WO2002078720A3 Antibiotics from bacteria isolated from amphibian skin
12/05/2002	WO2002070557A3 Nuclear hormone receptor ligand binding domain
12/05/2002	WO2002068470A3 Interferon-alpha induced gene
12/05/2002	WO2002064757A3 Influenza viruses with enhanced transcriptional and replicational capacities
12/05/2002	WO2002060924A9 Identification and applications of porcine reproductive and respiratory syndrome virus host susceptibility factor(s) for improved swine breeding and development of a non-simian recombinant cell line for propagation of the virus and a target for a novel class of antiviral compounds
12/05/2002	WO2002059146A3 Peptides having affinity for the gp120 viral protein and use thereof
12/05/2002	WO2002059116A3 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections
12/05/2002	WO2002056902A3 Ccr5 antagonist and dp-178 polypeptide for treating viral infections
12/05/2002	WO2002055675A8 Ancillary composition for the preparation of committed mature dendritic cells
12/05/2002	WO2002053110A3 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
12/05/2002	WO2002051866A3 Antibacterial treatments
12/05/2002	WO2002051819A3 Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them
12/05/2002	WO2002040511A3 Dna sequence and microcine from escherichia coli strain dsm 6601
12/05/2002	WO2002036073A3 Receptor antagonist-lipid conjugates and delivery vehicles containing same
12/05/2002	WO2002028902A3 Nectin polypeptides, polynucleotides, methods of making and use thereof
12/05/2002	WO2002020766A3 G-csf analog compositions and methods
12/05/2002	WO2001098362A3 Chemically-modified antimicrobial peptides, compositions and methods of production and use
12/05/2002	WO2001093840A2 Ligands of integrin receptors
12/05/2002	WO2001091798A3 Tumor activated prodrug compounds
12/05/2002	WO2001088180A3 Tnf and ifn stimulated genes and uses therefor
12/05/2002	WO2001034193A9 Plant lectins as mucosal adjuvants
12/05/2002	US20020183808 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant
12/05/2002	US20020183524 Preparations and use of an Ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/05/2002	US20020183508 Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
12/05/2002	US20020183503 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of immunological, infectious, inflammatory and cancer disorders
12/05/2002	US20020183399 Method and compositions for treating rosacea
12/05/2002	US20020183387 Topically applying to the affected area in the nail a lower alcohol and a lower carboxylic acid to treat the bacterial or fungal infection
12/05/2002	US20020183365 Therapy or ameliorating an indication of the invention in an animal, including a human, comprising administering heteroaryl compond
12/05/2002	US20020183267 For use as antibiotics; for therapy of Staphylococcus aureas infection
12/05/2002	US20020183263 Nutritional preparation comprising ribose and medical use thereof
12/05/2002	US20020183248 Locally administering to a cutaneous site at least one lectin capable of interfering with the infective capability of a pathogenic microorganism toward dermal tissue, in an amount effective to diminish infective capability microorganism
12/05/2002	US20020183246 Use of thiamphenicol for the preparation of a pharmaceutical useful for the treatment of vancomycin- intermediates and multiresistant staphylococci infections
12/05/2002	US20020183245 For therapy of Porphyromonas (Bacteroides) gingivalis; periodontal disorder
12/05/2002	US20020182706 Purification of viral envelope proteins; obtain cell, transfect with genetically engineered virus, lyse cell, recover envelope proteins
12/05/2002	US20020182581 Treating blood or blood products with compounds which have a mustard, aziridinium or aziridine group and a nucleic acid binding group
12/05/2002	US20020182276 Morinda citrifolia (Noni) enhanced animal food product
12/05/2002	US20020182274 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
12/05/2002	US20020182269 Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance
12/05/2002	US20020182265 Lubricious coatings for substrates
12/05/2002	US20020182255 Especially a sustained release composition for the treatment of ocular and periocular infections.
12/05/2002	US20020182228 Methods for producing self-replicating infectious RSV particles comprising recombinant RSV genomes or antigenomes and the N, P, L, and M2 proteins
12/05/2002	US20020182221 Recombinant papillomavirus vaccine and method for production and treatment
12/05/2002	US20020182216 Eliciting a T-cell mediated immune response in an animal, comprising administering to the animal an extract of an egg comprising transfer factor generated by said source animal
12/05/2002	US20020182208 Glycosylated antibody
12/05/2002	US20020182181 Generated from a bacteriophage; gene expression inhibition
12/05/2002	US20020182180 Method for inducing immunity to viruses
12/05/2002	US20020182177 Methods and compositions for promoting the maturation of monocytes
12/05/2002	US20020182176 Methods and compositions for promoting the maturation of monocytes
12/05/2002	US20020182175 Administration of a reactive oxygen species (ROS) inhibitor or scavenger (a histmine or its salt, ester, prodrug and agonist) and at least one monocyte maturation promoting agent (a cytokine)
12/05/2002	US20020182174 Methods and compositions for promoting the maturation of monocytes

1 ... 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 ... 1798